Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.43 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.43 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465325 | 0.89 | TSHR (0.71) | TSHRCYP2A6HTR2CMAOBMAOA | |
| SCHEMBL33555 | 0.89 | — | — | |
| SCHEMBL29351986 | 0.89 | — | — | |
| SCHEMBL34906 | 0.89 | — | — | |
| Methylamine SCHEMBL2462109 | 0.87 | TSHR (0.71) | TSHRCYP2A6HTR2CMAOBMAOA | |
| Ammonia Solution, Strong SCHEMBL330529 | 0.85 | — | — | |
| SCHEMBL31294878 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL21176564 | 0.85 | TSHR (0.67) | TSHRCYP2A6HTR2CMAOBMAOA | |
| Water SCHEMBL1168306 | 0.85 | — | — | |
| Bromide SCHEMBL917076 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850367-B | Purification method of PSMA inhibitor and application thereof | 北京先通国际医药科技股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| EP-1756096-B1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-08-12 | — | — | EP | disclosed |
| US-7485652-B2 | Indolyl derivatives as liver-X-receptor (LXR) modulators | HOFFMANN-LA ROCHE INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080214845-A1 | ANTIBACTERIAL 6'-MODIFIED 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20070099916-A1 | Indolyl derivatives as liver-x-receptor (LXR) modulators | DEHMLOW HENRIETTA | 2007-05-03 | — | — | US | disclosed |
| WO-2007028012-A2 | ANTIBACTERIAL 6'-N-MODIFIED 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1756096-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-7173048-B2 | Indolyl derivatives as liver-X-receptor (LXR) modulators | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| CN-1292503-C | Electrode material for rechanging lithium cell, and its use | CANON KK (JP) | 2006-12-27 | — | — | CN | disclosed |
| WO-2005105791-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245515-A1 | Indolyl derivatives as liver-X-receptor (LXR) modulators | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | US | disclosed |
| CN-1444301-A | Electrode material for rechanging lithium cell, and its use | CANON KK (JP) | 2003-09-24 | — | — | CN | disclosed |
| US-5837726-A | Antifungal agents derived from aspergillus fumigatus | MILLENNIUM PHARMACEUTICALS, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0249349-B1 | DIFLUOROKETO COMPOUNDS | ICI AMERICAS INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| US-4923890-A | Difluoro keto compounds and their use as HLE inhibitors | ICI AMERICAS INC. (US) | 1990-05-08 | — | — | US | disclosed |
| EP-0249349-A1 | Difluoroketo compounds | ICI AMERICAS INC. (US) | 1987-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245515-A1 | Indolyl derivatives as liver-X-receptor (LXR) modulators | INSR, NR1H2, NR1H3 | TSHR 100/4885CYP2A6 158/4885HTR2C 1032/4885 |
| US-20070099916-A1 | Indolyl derivatives as liver-x-receptor (LXR) modulators | INSR, NR1H2, NR1H3 | TSHR 100/4885CYP2A6 158/4885HTR2C 1032/4885 |
| US-20080214845-A1 | ANTIBACTERIAL 6'-MODIFIED 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS | FUT6, ALG8, NRDC | TSHR 4244/4885CYP2A6 316/4885HTR2C 4543/4885 |
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, JAK2 | TSHR 713/4885CYP2A6 1374/4885HTR2C 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.